The Use of Peptide Receptor Radionuclide Therapy in Patients With Neuroendocrine Tumor Cardiac Metastases
- Resource Type
- Authors
- Irene S Yu; Hagen F. Kennecke; Eugene Lin; Gayle Funk
- Source
- Clinical Nuclear Medicine. 46:e23-e26
- Subject
- Male
Oncology
medicine.medical_specialty
Receptors, Peptide
Peptide receptor
Neuroendocrine tumors
030218 nuclear medicine & medical imaging
Metastasis
Heart Neoplasms
03 medical and health sciences
0302 clinical medicine
Positron Emission Tomography Computed Tomography
Internal medicine
Organometallic Compounds
Humans
Medicine
Radiology, Nuclear Medicine and imaging
In patient
business.industry
General Medicine
medicine.disease
Neuroendocrine Tumors
030220 oncology & carcinogenesis
Radionuclide therapy
Female
business
- Language
- ISSN
- 1536-0229
0363-9762
Cardiac metastases are an infrequent site of metastasis in neuroendocrine tumors, and the treatment implications in the era of peptide receptor radionuclide therapy (PRRT) are unclear. Potential safety concerns exist regarding cardiac integrity and function in response to PRRT. We describe our institutional experience with 4 patients with well-differentiated, midgut neuroendocrine tumors with cardiac involvement detected on Ga-DOTATATE PET/CT scans who were treated with PRRT.